Quality of life, long-term survivors and long-term outcome from the ABC-02 study-Reference-Cited by-同舟云学术

Quality of life, long-term survivors and long-term outcome from the ABC-02 study

Published:2016-04 Issue:9 Volume:114 Page:965-971
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bridgewater John, ,Lopes Andre,Palmer Daniel,Cunningham David,Anthoney Alan,Maraveyas Anthony,Madhusudan Srinivasan,Iveson Tim,Valle Juan,Wasan Harpreet

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201664.pdf

Reference17 articles.

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes J. C. J. M. D., Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 85: 365–376.

2. Cuzick J (1985) A Wilcoxon-type test for trend. Stat Med 4 (1): 87–90.

3. de Groen PC, Gores GJ, Larusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368–1378.

4. Eckel F, Brunner T, Jelic S ESMO Guidelines Working Group (2011) Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22: vi40–vi44.

5. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Büchler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 35: 939–941.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma;Pharmaceuticals;2024-07-08

2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet Oncology;2024-05

3. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy;Gut;2023-09-27

4. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer;Targeted Oncology;2023-09-26

5. Emerging treatment strategies in hepatobiliary cancer;Expert Review of Anticancer Therapy;2023-03-01